Table 7.
Pathways enriched by miRNA target genes in the IL-1ß/IL-10-based ASD subgroups.
| IL-1ß/IL-10 ratio | Pathways revealed enrichment by miRNA target genes1 |
| High-ratio ASD subgroup only | Renal cell carcinoma, melanoma Intracellular trafficking and secretion 2 mTOR signaling pathway 2 , insulin signaling pathway 2 |
| Low-ratio ASD subgroup only | Ubiquitin-mediated proteolysis 2 , adherens junction 2 |
| Both high- and low-ratio ASD subgroups | Endocytosis2, focal adhesion2, TGF-ß signaling pathway2 WNT signaling pathway2
Chronic myeloid leukemia, pancreatic cancer, oocyte meiosis Colorectal cancer |
| Normal-ratio ASD subgroup only4 | None |
| All ASD samples combined | Pathways in cancer, prostate cancer, non-small cell lung cancer, glioma, ErB signaling pathway Neurotrophin signaling pathway 3 , axon guidance 3 MAPK signaling pathway 2 |
1Revealed enrichment by target genes by miRNAs that revealed >2-fold DEs as compared to non-ASD controls by Bonferroni test (p < 0.001).
2Pathways associated with key immune functions and metabolic regulation
3Pathways associated with synaptic formation and neuronal plasticity.
4Normal IL-1ß/IL-10 ratio ASD groups—no subgroup specific pathway was found in this group. Pathways associated are the same as shown in all ASD samples.